Skip to main content

Table 3 The association between MHR and MACE

From: Monocyte to high-density lipoprotein cholesterol ratio predicts poor outcomes in ischaemic heart failure patients combined with diabetes: a retrospective study

 

Model 1

Model 2

Model 3

HR (95% CIs)

P

P for trend

HR (95% CIs)

P

P for trend

HR (95% CIs)

P

P for trend

MACE

  

 < 0.001

  

 < 0.001

  

 < 0.001

 Quartile 1: MHR < 0.33

1.0 (Ref)

  

1.0 (Ref)

  

1.0 (Ref)

  

 Quartile 2: 0.33 ≤ MHR < 0.46

1.66 (1.20–2.29)

0.002

 

1.66 (1.20–2.30)

0.002

 

1.59 (1.15–2.22)

0.006

 

 Quartile 3: 0.46 ≤ MHR < 0.62

2.00 (1.47–2.74)

 < 0.001

 

2.04 (1.48–2.80)

 < 0.001

 

1.89 (1.37–2.62)

 < 0.001

 

 Quartile 4: MHR ≥ 0.62

2.82 (2.09–3.80)

 < 0.001

 

2.83 (2.09–3.29)

 < 0.001

 

2.29 (1.66–3.18)

 < 0.001

 

 Continuous

3.03 (2.20–4.18)

 < 0.001

 

1.74 (2.08–3.85)

 < 0.001

 

2.11 (1.47–3.03)

 < 0.001

 

All-cause mortality

  

 < 0.001

  

 < 0.001

  

0.003

 Quartile 1: MHR < 0.33

1.0 (Ref)

  

1.0 (Ref)

  

1.0 (Ref)

  

 Quartile 2: 0.33 ≤ MHR < 0.46

1.66 (1.06–2.61)

0.028

 

1.69 (1.07–2.67)

0.026

 

1.66 (1.04–2.66)

0.035

 

 Quartile 3: 0.46 ≤ MHR < 0.62

2.02 (1.30–3.14)

0.002

 

2.07 (1.32–3.26)

0.002

 

1.98 (1.25–3.13)

0.003

 

 Quartile 4: MHR ≥ 0.62

2.50 (1.63–3.85)

 < 0.001

 

2.56 (1.65–3.99)

 < 0.001

 

2.05 (1.28–3.29)

0.003

 

 Continuous

2.85 (1.78–4.56)

 < 0.001

 

2.80 (1.74–4.50)

 < 0.001

 

1.94 (1.14–3.29)

0.015

 

Nonfatal MI

  

0.002

  

0.004

  

0.006

 Quartile 1: MHR < 0.33

1.0 (Ref)

  

1.0 (Ref)

  

1.0 (Ref)

  

 Quartile 2: 0.33 ≤ MHR < 0.46

1.97 (0.66–5.89)

0.223

 

1.91 (0.63–5.76)

0.253

 

1.79 (0.58–5.48)

0.308

 

 Quartile 3: 0.46 ≤ MHR < 0.62

2.76 (0.97–7.85)

0.056

 

2.68 (0.93–7.75)

0.068

 

2.53 (0.86–7.42)

0.091

 

 Quartile 4: MHR ≥ 0.62

4.16 (1.53–11.29)

0.005

 

3.99 (1.44–11.09)

0.008

 

3.90 (1.35–11.28)

0.012

 

 Continuous

4.56 (1.85–11.23)

0.001

 

1.54 (1.15–2.05)

0.004

 

4.53 (1.66–12.39)

0.003

 

Any revascularization

  

 < 0.001

  

 < 0.001

  

0.001

 Quartile 1: MHR < 0.33

1.0 (Ref)

  

1.0 (Ref)

  

1.0 (Ref)

  

 Quartile 2: 0.33 ≤ MHR < 0.46

1.60 (0.97–2.63)

0.066

 

1.58 (0.95–2.62)

0.077

 

1.52 (0.91–2.54)

0.108

 

 Quartile 3: 0.46 ≤ MHR < 0.62

1.85 (1.14–3.03)

0.013

 

1.87 (1.13–3.07)

0.014

 

1.70 (1.02–2.81)

0.040

 

 Quartile 4: MHR ≥ 0.62

2.94 (1.86–4.65)

 < 0.001

 

2.91 (1.82–4.65)

 < 0.001

 

2.31 (1.40–3.81)

0.001

 

 Continuous

2.90 (1.75–4.79)

 < 0.001

 

2.72 (1.64–4.51)

 < 0.001

 

1.93 (1.10–3.39)

0.023

 
  1. Models were derived from Cox proportional hazards regression analysis. Model 1: unadjusted. Model 2: adjusted for age, sex. Model 3: adjusted for age, sex, heart rate, body mass index, LVDd, LM disease, chronic total occlusion, diffuse lesion, target vessel of LM, complete revascularization, number of stents, total bilirubin, direct bilirubin, TC, triglyceride glucose, platelet, ARB, sacubitril/valsartan, metformin, SGLT2 inhibitor. HR, hazards ratio; CI, confidence interval; MACE, major adverse cardiovascular events; Ref, as reference; MHR, monocyte to high-density lipoprotein cholesterol ratio; MI, myocardial infarction; LVDd, Left ventricular end diastolic diameter; LM, left main artery; TC, total cholesterol; ARB, angiotensin receptor blocker; SGLT2, sodium-glucose cotransporter 2
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us